Moderna Q1 preview: revenue rebound in focus as losses persist

Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to ...

Moderna Gears Up to Report Q1 Earnings: Here's What to Expect

MRNA heads into Q1 earnings with expected sales growth, new vaccine momentum and focus on pipeline updates amid tough RSV competition.
The Tuscaloosa News

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...

Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal?

Investors may be wondering whether Moderna's current share price reflects its true value, or if the market is still trying to ...